Drugs / Levodopa-carbidopa intestinal gel
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00660387 | Dec 2009 → Oct 2011 | Parkinson disease | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levodopa-carbidopa intestinal gel | “levodopa-carbidopa intestinal gel (LCIG) provides continuous infusion and reduces "off" time in advanced Parkinson's disease (PD) patients with motor fluctuations despite...” PMID 25962554 ↗ Apr 2015 |
| Known as | LCIG | “Levodopa carbidopa intestinal gel (LCIG)” NCT00660387 ↗ |